[1] |
Samak M, Fatullayev J, Sabashnikov, A, et al. Cardiac hypertrophy: an introduction to molecular and cellular basis[J]. Med Sci Monit Basic Res, 2016, 22: 75-79.
|
[2] |
Tham, YK, Bernardo BC, Ooi JY, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets[J]. Arch Toxicol, 2015, 89(9): 1401-1438.
|
[3] |
Yan K, Wang K, Li P. The role of post-translational modifications in cardiac hypertrophy[J]. J Cell Mol Med, 2019, 23(6): 3795-3807.
|
[4] |
Zhang QJ, Tran TAT, Wang M, et al. Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis [J]. Nat Commun, 2018, 9(1): 5230.
|
[5] |
Nomura S, Satoh M, Fujita T, et al. Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failure[J]. Nat Commun, 2018, 9(1): 4435.
|
[6] |
Gallo S, Vitacolonna A, Bonzano A, et al. ERK: a key player in the pathophysiology of cardiac hypertrophy [J]. Int J Mol Sci, 2019, 20(9): 2164-2184.
|
[7] |
Zhang Y, Zhang L, Fan X, et al. Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/ β-catenin and Jak2/Stat3 pathways[J]. Biomed Pharmacother, 2019, 113: 108780.
|
[8] |
Ju S, Park S, Lim L, et al. Low density lipoprotein receptor-related protein 1 regulates cardiac hypertrophy induced by pressure overload[J]. Int J Cardiol, 2020, 299: 235-242.
|
[9] |
李依琪, 李 乐. 青藤碱对异丙肾上腺素诱导小鼠心肌肥厚的影响[J]. 中国病理生理杂志, 2018, 34(6): 547-549.
|
[10] |
Kresoja KP, Schmidt G, Kherad B, et al. Acute and chronic heart failure[J]. Herz, 2017, 42(7): 699-712.
|
[11] |
Nakagawa Y, Nishikimi T, Sakai H, et al. Macro-pro-B-type natriuretic peptide (proBNP) and hidden macro-N-terminal proBNP: Case report [J]. Clin Biochem, 2018, 52: 148-152.
|
[12] |
Courand PY, Harbaoui B, Bècle C, et al. Plasma NT-proBNP mirrors the deleterious cardiovascular and renal continuum in hypertension [J]. Eur J Prev Cardiol, 2017, 24(5): 452-459.
|
[13] |
Tamura S, Marunouchi T, Tanonaka K. Heat-shock protein 90 modulates cardiac ventricular hypertrophy via activation of MAPK pathway [J]. J Mol Cell Cardiol, 2019, 127: 134-142.
|
[14] |
Sala V, Gallo S, Gatti S, et al. Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib[J]. J Mol Cell Cardiol, 2016, 93: 84-97.
|
[15] |
Li C, Chen Z, Yang H, et al. Selumetinib, an oral anti-neoplastic drug, may attenuate cardiac hypertrophy via targeting the erk pathway [J]. PLoS One, 2016, 11(7): e0159079.
|